5.60
price down icon2.61%   -0.15
after-market Dopo l'orario di chiusura: 5.56 -0.04 -0.71%
loading
Precedente Chiudi:
$5.75
Aprire:
$5.78
Volume 24 ore:
877.29K
Relative Volume:
0.92
Capitalizzazione di mercato:
$280.56M
Reddito:
$124.00K
Utile/perdita netta:
$-49.99M
Rapporto P/E:
-3.3136
EPS:
-1.69
Flusso di cassa netto:
$-31.03M
1 W Prestazione:
-5.72%
1M Prestazione:
+6.06%
6M Prestazione:
+26.41%
1 anno Prestazione:
-30.35%
Intervallo 1D:
Value
$5.55
$5.98
Intervallo di 1 settimana:
Value
$5.365
$6.03
Portata 52W:
Value
$3.785
$14.60

Candel Therapeutics Inc Stock (CADL) Company Profile

Name
Nome
Candel Therapeutics Inc
Name
Telefono
617-916-5445
Name
Indirizzo
117 KENDRICK STREET, NEEDHAM
Name
Dipendente
38
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
CADL's Discussions on Twitter

Confronta CADL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CADL
Candel Therapeutics Inc
5.60 297.61M 124.00K -49.99M -31.03M -1.69
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.27 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.85 114.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3499 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
83.98 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
484.93 63.90B 14.09B 4.50B 2.96B 39.28

Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-20 Iniziato Citigroup Buy
2025-02-19 Iniziato Canaccord Genuity Buy
2025-02-07 Iniziato BofA Securities Buy
2022-12-02 Iniziato H.C. Wainwright Buy
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-08-23 Iniziato Credit Suisse Outperform
2021-08-23 Iniziato Jefferies Buy
2021-08-23 Iniziato UBS Buy
Mostra tutto

Candel Therapeutics Inc Borsa (CADL) Ultime notizie

pulisher
Jun 03, 2025

CADL to Present Phase 3 Prostate Cancer Trial Insights | CADL Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 02, 2025

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - Yahoo Finance

Jun 02, 2025
pulisher
Jun 02, 2025

Deutsche Bank AG Boosts Stake in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World

Jun 02, 2025
pulisher
May 30, 2025

Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer - MSN

May 30, 2025
pulisher
May 29, 2025

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - sharewise

May 29, 2025
pulisher
May 29, 2025

Candel Therapeutics (CADL) Gains on FDA RMAT Designation for CAN-2409 - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga

May 29, 2025
pulisher
May 29, 2025

Candel Therapeutics gains FDA RMAT status for prostate cancer therapy By Investing.com - Investing.com South Africa

May 29, 2025
pulisher
May 29, 2025

(CADL) Trading Report - news.stocktradersdaily.com

May 29, 2025
pulisher
May 28, 2025

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy By Stocktwits - Investing.com India

May 28, 2025
pulisher
May 28, 2025

Small cap wrap: Midnight Sun Mining, MustGrow Biologics, Candel Therapeutics, HIVE... - Proactive financial news

May 28, 2025
pulisher
May 28, 2025

Market movers: GameStop, Okta, Abercrombie, Candel Therapeutics... - Proactive financial news

May 28, 2025
pulisher
May 28, 2025

Candel Says FDA Grants Regenerative Medicine Advanced Therapy Designation to Prostate Cancer Drug - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Candel stock gains after FDA RMT designation (CADL:NASDAQ) - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy - MSN

May 28, 2025
pulisher
May 28, 2025

Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On? - Benzinga

May 28, 2025
pulisher
May 28, 2025

Candel Therapeutics get FDA’s RMAT designation for prostate cancer therapy - Proactive financial news

May 28, 2025
pulisher
May 28, 2025

Candel Therapeutics (CADL) Receives RMAT Designation for CAN-2409 in Prostate Cancer | CADL Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Candel Therapeutics Receives FDA RMAT Designation for CAN-2409 - TipRanks

May 28, 2025
pulisher
May 28, 2025

Candel Therapeutics gains FDA RMAT status for prostate cancer therapy - Investing.com

May 28, 2025
pulisher
May 28, 2025

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer - The Manila Times

May 28, 2025
pulisher
May 28, 2025

Candel Therapeutics Receives FDA Regenerative Medicine - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Breakthrough: FDA Fast-Tracks Revolutionary Prostate Cancer Therapy Showing 80% Complete Response Rate - Stock Titan

May 28, 2025
pulisher
May 28, 2025

Northern Trust Corp Purchases 6,250 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World

May 28, 2025
pulisher
May 27, 2025

Candel Therapeutics (CADL) to Reveal Positive Phase 3 Results fo - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Candel Therapeutics (CADL) to Reveal Positive Phase 3 Results for Prostate Cancer | CADL Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Candel Therapeutics to Host Investor Conference Call - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

Candel Therapeutics to host June 3 call on positive Phase 3 results for prostate cancer therapy - Proactive Investors

May 27, 2025
pulisher
May 27, 2025

Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know - MSN

May 27, 2025
pulisher
May 27, 2025

Candel Therapeutics: CAN-2409’s Promising Progress Deserves An Upgrade (NASDAQ:CADL) - Seeking Alpha

May 27, 2025
pulisher
May 26, 2025

Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 - MSN

May 26, 2025
pulisher
May 25, 2025

Candel Therapeutics (NASDAQ:CADL) Upgraded at Wall Street Zen - Defense World

May 25, 2025
pulisher
May 23, 2025

Small cap wrap: Excellon Resources, Candel Therapeutics, Forte Minerals... - Proactive financial news

May 23, 2025
pulisher
May 23, 2025

Candel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025 - Proactive financial news

May 23, 2025
pulisher
May 22, 2025

Candel Therapeutics Unveils Promising Phase 3 Trial Results - TipRanks

May 22, 2025
pulisher
May 22, 2025

Candel Therapeutics to Present Positive Phase 3 Clinical Trial Results of CAN-2409 for Prostate Cancer at ASCO 2025 - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

Breakthrough Phase 3 Results: First Successful Prostate Cancer Trial in 20 Years Shows 30% Lower Recurrence Risk - Stock Titan

May 22, 2025
pulisher
May 19, 2025

Best Momentum Stocks to Buy for May 19th - The Globe and Mail

May 19, 2025
pulisher
May 19, 2025

New Strong Buy Stocks for May 19th - The Globe and Mail

May 19, 2025
pulisher
May 15, 2025

CADL To Present Prostate Cancer Trial Data, RMD's Q3 Revenue Climbs 8%, AUNA On Watch... - RTTNews

May 15, 2025
pulisher
May 14, 2025

Promising Pipeline Developments and Strong Data Support Buy Rating for Candel Therapeutics - TipRanks

May 14, 2025
pulisher
May 14, 2025

Small cap wrap: Candel Therapeutics, Nevis Brands, Fineqia, Voyageur Pharmaceuticals, atai... - Proactive financial news

May 14, 2025
pulisher
May 14, 2025

Candel Therapeutics Reports Strong Q1 2025 Results - TipRanks

May 14, 2025
pulisher
May 13, 2025

CADL's Cash Reserves Projected to Last Until Early 2027 | CADL S - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish - NewsBreak: Local News & Alerts

May 13, 2025
pulisher
May 13, 2025

Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish By Stocktwits - Investing.com India

May 13, 2025
pulisher
May 13, 2025

Candel Therapeutics (CADL) Reports Q1 Earnings and Cash Reserves - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Market movers: Coinbase, Hertz, Candel Therapeutics, JD Sports... - Proactive Investors

May 13, 2025
pulisher
May 13, 2025

Cardell Flat on Q1 - Baystreet.ca

May 13, 2025

Candel Therapeutics Inc Azioni (CADL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.16
price up icon 0.00%
$573.50
price down icon 0.54%
$36.08
price up icon 15.90%
$305.31
price up icon 0.51%
$4.75
price up icon 3.70%
$484.93
price down icon 0.60%
Capitalizzazione:     |  Volume (24 ore):